Table 3 Validated cancer-miRNA modules

1

{miR-100}→ {miR-125b}

urothelial(U,U)

[75]

2

{miR-125b, let-7a-2} → {miR-21}

HCC(D,D,U)

[76]

4

{miR-143}→ {miR-21}

oral squamous cell carcinoma(D,U)

[77]

4

{miR-143}→ {miR-21}

HCC(D,U)

[76]

5

{miR-143, miR-145} → {miR-21, miR-125b}

oral squamous cell carcinoma(D,D,U,D)

[77]

5

{miR-143, miR-145} → {miR-21, miR-125b}

prostate(D,D,U,D)

[21, 78–80]

5

{miR-143, miR-145} → {miR-21, miR-125b}

HCC(D,D,U,D)

[76]

6

{miR-17-5p, miR-20a} → {miR-143, miR-145}

leukemia(U,U,D,D)

[81, 82]

8

{miR-101, miR-210} → {let-7a-2}

colon(D,U,D)

[83–85]

8

{miR-101, miR-210} → {let-7a-2}

prostate(D,U,D)

[83, 86]

8

{miR-101, miR-210} → {let-7a-2}

melanoma(D,U,D)

[42, 83, 84, 87]

8

{miR-101, miR-210} → {let-7a-2}

HCC(D,U,D)

[76]